• Lia Amalia Bandung Institute of Technology
  • Ilil Maidatuz Zulfa Department of Pharmacology and Clinical Pharmacy, Bandung Institute of Technology (ITB), Bandung, Indonesia
  • Arto Yuwono Soeroto Dr. Hasan Sadikin General Hospital


Objective: Kanamycin and capreomycin are the second lines injectable ant tuberculosis used in therapy regimen of multidrug resistance tuberculosis (MDR TB) in Indonesia. Both have effects on serum potassium levels and cause hypokalemia. The aim of this study is to compare and evaluate the effects of kanamycin and capreomycin on serum potassium levels of MDR TB patient.

Methods: This was a retrospective and concurrent cohort study with intention-to-treat analysis on MDR TB patients during 2014 at Dr. Hasan Sadikin General Hospital Bandung, Indonesia. The patients were divided into two groups, one group received kanamycin regimen. Meanwhile, the other group received capreomycin regimen. Serum potassium level, the incidence of hypokalemia and the classification of its severity were compared monthly for five months of the therapy.

Results: In the first two months, capreomycin significantly decreased serum potassium level stronger than kanamycin (2.95 mEq/l vs. 3.82 mEq/l, P<0.001 in the first month and 2.85 mEq/l vs. 3.81 mEq/l, P<0.001 in the second month). Before five months, the number of enabled patients to follow up decline which is caused by hypokalemia in capreomycin group was60.0% while in kanamycin group is 0.0%.

Conclusion: Capreomycin has a stronger effect on decreasing serum potassium level compared to kanamycin, and it causes hypokalemia.


Keywords: Second line Injectable Antituberculosis, Adverse Drug Reaction, Hypokalemia


Download data is not yet available.


1. Katherine F, Annabel B, Anna D, Hannah MD, Dennis F, Inés G, et al. editors. Global tuberculosis report. France: WHO Library Cataloguing-in-Publication Data; 2013.
2. Jose AC, Giovani S, Alimuddin Z, Giovani BM. Best drug treatment for multi-drug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis 2010;10:621-9.
3. Sonya S, Jennifer F, Felix A, Anne H, Keith J, Epifanio S, et al. Hypokalemia among patients receiving treatment for multi-drug resistant tuberculosis. Chest 2004;125:974-80.
4. Shin SS, Pasechnikov AD, Gelmanova IY, Peremitin GG, Strelis AK, Mishutin S, et al. Adverse reactions among patients being treated for MDR-TB in Tomsk, Rusia. Int J Tuberculosis Lung Dis 2007;11:1314-20.
5. Haregewoin B, Daniel S, Getnet Y, Tesfamariam M. Prevalence and risk factors of adverse drug reactions associated multidrug-resistant tuberculosis treatments in selected treatment centers in addis ababa ethiopia. J Tuberc Res 2014;2:144-54.
6. Helen S, Rustam R. Hypokalemia in adults. Share Care Pathology Guidelines CHISCP6; 2012.
7. Zietse R, Zoutendijk R, Hoorn EJ. Fluid, electrolyte and acid-based disorders associated with antibiotic therapy. Nat Rev Nephrol 2009;5:193-202.
8. Zuzana S, Michel B, Saiid K, Romuald M. Agonist and allosteric modulators of the calcium-sensing receptor and their therapeutic applications. Mol Pharm 2009;76:1131-44.
562 Views | 1136 Downloads
How to Cite
Amalia, L., I. M. Zulfa, and A. Y. Soeroto. “COMPARATIVE STUDY OF KANAMYCIN AND CAPREOMYCIN ON SERUM POTASSIUM LEVEL OF MULTIDRUG RESISTANCE TUBERCULOSIS PATIENTSAT A HOSPITAL IN BANDUNG, INDONESIA”. International Journal of Pharmacy and Pharmaceutical Sciences, Vol. 8, no. 1, Jan. 2016, pp. 307-10,
Original Article(s)